Keyphrases
Patient Management
100%
Ceftaroline
100%
Methicillin-resistant Staphylococcus Aureus Pneumonia
100%
Community-acquired Pneumonia
75%
Methicillin-resistant Staphylococcus Aureus
62%
Vancomycin
25%
Pneumonia
25%
Ventilator-associated Pneumonia
25%
Linezolid
25%
Lactams
25%
Real-world Outcomes
25%
Adverse Events
12%
In Vitro Activity
12%
Antibiotics
12%
Recommended Treatment
12%
Randomized Controlled Trial
12%
Published Data
12%
High Mortality Rate
12%
Systematic Literature Review
12%
Bacteremia
12%
Severe Disease
12%
Gram-positive Bacteria
12%
Pneumonia Ventilator-associated
12%
Empyema
12%
Skin Tissue
12%
Extended-spectrum Cephalosporins
12%
Specific Scenario
12%
Healthcare-associated Infections
12%
Complicating Factors
12%
Soft Tissue Infection
12%
Community-acquired Infections
12%
Disease-specific Mortality
12%
Acute Kidney Injury
12%
Clostridium Difficile Infection
12%
Medicine and Dentistry
Systematic Review
100%
Methicillin Resistant Staphylococcus Aureus Infection
100%
Ceftaroline Fosamil
100%
Methicillin Resistant Staphylococcus Aureus
71%
Community-Acquired Pneumonia
57%
Hospital-Acquired Pneumonia
28%
Ventilator-Associated Pneumonia
28%
Linezolid
28%
Lactam
28%
Vancomycin
28%
Adverse Event
14%
Disease
14%
Mortality Rate
14%
Antibiotics
14%
Randomized Controlled Trial
14%
Gram-Positive Bacteria
14%
Ceftaroline
14%
Bacteremia
14%
In Vitro
14%
Empyema
14%
Cephalosporin
14%
Acute Kidney Injury
14%
Clostridium Difficile Infection
14%
Soft Tissue Infection
14%
Community Acquired Infection
14%
Healthcare Associated Infection
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ceftaroline Fosamil
100%
Methicillin Resistant Staphylococcus Aureus Infection
100%
Methicillin-Resistant Staphylococcus Aureus
71%
Community Acquired Pneumonia
57%
Vancomycin
28%
Ventilator Associated Pneumonia
28%
Hospital Acquired Pneumonia
28%
Linezolid
28%
Lactam
28%
Disease
14%
Antibiotic Agent
14%
Mortality Rate
14%
Adverse Event
14%
Bacteremia
14%
Acute Kidney Failure
14%
Ceftaroline
14%
Cephalosporin
14%
Randomized Controlled Trial
14%
Empyema
14%
Gram Positive Bacterium
14%
Healthcare Associated Infection
14%
Community Acquired Infection
14%
Soft Tissue Infection
14%
Clostridium Difficile Infection
14%
Immunology and Microbiology
Methicillin-Resistant Staphylococcus Aureus
100%
Mortality Rate
12%
Gram-Positive Bacteria
12%
Peptoclostridium difficile
12%
Empyema
12%
Soft Tissue
12%